Literature DB >> 15821839

Administration of vascular endothelial growth factor adjunctive to fetal cardiomyocyte transplantation and improvement of cardiac function in the rat model.

Alexander Schuh1, Sebastian Breuer, Raja Al Dashti, Nasir Sulemanjee, Peter Hanrath, Christian Weber, Barry F Uretsky, Ernst R Schwarz.   

Abstract

BACKGROUND: The functional impact of cellular transplantation and the potential role of the addition of angiogenic factors for survival of engrafts remain controversial.
METHODS: Vascular endothelial growth factor (VEGF) (25 ng/mL) was added to cultured fetal cardiomyocytes labeled with bromodeoxyuridine (BrDU), which was injected into the border zones of myocardial infarction 4 weeks after coronary occlusion in rat hearts. Group 1 (n = 12) received cells plus VEGF protein (100 ng), group 2 (n = 12) received cells without VEGF, group 3 (n = 10) received VEGF without cells, and group 4 (n = 12) received pure culture medium. Cardiac function was then assessed by transthoracic two-dimensional echocardiography and Langendorff perfusion system. In situ hybridization for Y chromosomes of transplanted cells, detection of BrDU-labeled cells, and platelet/endothelial cell adhesion molecule-1 (PECAM-1) staining for endothelial cells was performed.
RESULTS: Echocardiography revealed smaller end-diastolic left ventricular dimensions in transplanted hearts in group 1 (0.83 +/- 0.13 cm 4 weeks after coronary occlusion before transplantation and 0.69 +/- 0.14 cm 2 months after transplantation, P < .05) and in group 2 (0.88 +/- 0.09 cm after coronary occlusion before transplantation and 0.76 +/- 0.08 cm 2 months after transplant), and increases in fractional shortening (34.2% +/- 8.53% before transplant and 45.3% +/- 10.9% after [P < .05] in group 1; 26.9% +/- 6.02% before transplant and 37.15% +/-8.08% after [P < .005] in group 2), whereas groups 3 and 4 showed a decrease in fractional shortening. Transplanted hearts developed higher pressures at rest (group 1, 96.8 +/- 20.8 mm Hg; group 2, 98.6 +/- 21.9 mm Hg) compared with controls (group 4, 70.9 +/- 25 mm Hg) (P < .05) and during inotropic stimulation (group 1, 111 +/- 19.5 mm Hg and group 2, 113.3 +/- 32.6 vs group 4, 80.7 +/- 31.6 mm Hg, P < .05). Histologic analysis demonstrated the presence of transplanted cells in border zones of infarcted host myocardium with neovascularization in all transplanted hearts.
CONCLUSION: Transplantation of fetal cardiomyocytes results in improvement of left ventricular function. The addition of VEGF does not contribute to further improvement of left ventricular function and angiogenesis in the present model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15821839     DOI: 10.1177/107424840501000107

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  9 in total

1.  Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats.

Authors:  S Fernandes; A V Naumova; W Z Zhu; M A Laflamme; J Gold; C E Murry
Journal:  J Mol Cell Cardiol       Date:  2010-09-18       Impact factor: 5.000

Review 2.  Heart failure management: the present and the future.

Authors:  Mohammad N Jameel; Jianyi Zhang
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

Review 3.  Therapeutic myocardial angiogenesis.

Authors:  Marie-Ange Renault; Douglas W Losordo
Journal:  Microvasc Res       Date:  2007-09-07       Impact factor: 3.514

Review 4.  Cardiac stem/progenitor cells, secreted proteins, and proteomics.

Authors:  Miroslava Stastna; M Roselle Abraham; Jennifer E Van Eyk
Journal:  FEBS Lett       Date:  2009-03-20       Impact factor: 4.124

Review 5.  Chemokine contribution in stem cell engraftment into the infarcted myocardium.

Authors:  Elisa A Liehn; Eugen Radu; Alexander Schuh
Journal:  Curr Stem Cell Res Ther       Date:  2013-07       Impact factor: 3.828

6.  Myocardial regeneration by transplantation of modified endothelial progenitor cells expressing SDF-1 in a rat model.

Authors:  Alexander Schuh; Andreas Kroh; Simone Konschalla; Elisa A Liehn; Radoslav M Sobota; Erik Al Biessen; Ilze Bot; Tolga Taha Sönmez; Sönmez Tolga Taha; Andreas Schober; Nikolaus Marx; Christian Weber; Alexander Sasse
Journal:  J Cell Mol Med       Date:  2012-10       Impact factor: 5.310

7.  Repetitive transplantation of different cell types sequentially improves heart function after infarction.

Authors:  Schuh Alexander; Alexander Sasse; Simone Konschalla; Andreas Kroh; Marc W Merx; Christian Weber; Elisa A Liehn
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

8.  Controlled intramyocardial release of engineered chemokines by biodegradable hydrogels as a treatment approach of myocardial infarction.

Authors:  Delia Projahn; Sakine Simsekyilmaz; Smriti Singh; Isabella Kanzler; Birgit K Kramp; Marcella Langer; Alexandrina Burlacu; Jürgen Bernhagen; Doris Klee; Alma Zernecke; Tilman M Hackeng; Jürgen Groll; Christian Weber; Elisa A Liehn; Rory R Koenen
Journal:  J Cell Mol Med       Date:  2014-02-06       Impact factor: 5.310

9.  Novel insights into the mechanism of cell-based therapy after chronic myocardial infarction.

Authors:  Alexander Schuh; Britta Butzbach; Adelina Curaj; Sakine Simsekyilmaz; Octavian Bucur; Isabela Kanzler; Bernd Deneke; Simone Konschalla; Andreas Kroh; Tolga Taha Sönmez; Nikolaus Marx; Elisa A Liehn
Journal:  Discoveries (Craiova)       Date:  2014-01-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.